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Microbes have developed resistance to nearly every antibiotic, yet the steps leading to drug resistance remain
unclear. Here we report a multistage process by which Pseudomonas aeruginosa acquires drug resistance
following exposure to ciprofloxacin at levels ranging from 0.5 to 8 the initial MIC. In stage I, susceptible
cells are killed en masse by the exposure. In stage II, a small, slow to nongrowing population survives antibiotic
exposure that does not exhibit significantly increased resistance according to the MIC measure. In stage III,
exhibited at 0.5 to 4 the MIC, a growing population emerges to reconstitute the population, and these cells
display heritable increases in drug resistance of up to 50 times the original level. We studied the stage III cells
by proteomic methods to uncover differences in the regulatory pathways that are involved in this phenotype,
revealing upregulation of phosphorylation on two proteins, succinate-semialdehyde dehydrogenase (SSADH)
and methylmalonate-semialdehyde dehydrogenase (MMSADH), and also revealing upregulation of a highly
conserved protein of unknown function. Transposon disruption in the encoding genes for each of these targets
substantially dampened the ability of cells to develop the stage III phenotype. Considering these results in
combination with computational models of resistance and genomic sequencing results, we postulate that stage
III heritable resistance develops from a combination of both genomic mutations and modulation of one or more
preexisting cellular pathways.
In the ongoing war between bug and drug, Pseudomonas
aeruginosa is a frequent victor because it rapidly develops new
defenses to any drug that is generated (31, 41). This is of grave
concern for prevention and spread of infectious disease and is
a significant mystery to bacteriologists. While there are a num-
ber of known resistance mechanisms that develop in P. aerugi-
nosa, the mystery stems from how these are rapidly generated
and accumulate in a population to quickly form high-level
resistance to an antimicrobial drug after exposure. Finding
solutions to inhibit the rise of resistance in P. aeruginosa is
important because the organism is responsible for chronic lung
infection in individuals with cystic fibrosis (CF) (6) or chronic
obstructive pulmonary disease (COPD) (13, 15, 28), and it
also accounts for nearly 10% of hospital-acquired infections
(47, 52).
There is a small set of drugs commonly used to treat P.
aeruginosa infection, including ciprofloxacin, tobramycin, gen-
tamicin, ceftazidime, and imipenem. While P. aeruginosa has
developed various levels of resistance to each of these, its
response to ciprofloxacin is of particular interest because the
drug is initially very effective, but P. aeruginosa rapidly acquires
high-level resistance, rendering the drug impotent. In clinical
isolates, approximately 30% of strains now present high-level
ciprofloxacin resistance (31).
While there have been many studies of factors involved in
ciprofloxacin resistance in P. aeruginosa (e.g., references 17, 22,
and 48), the series of steps and molecular mechanisms that
initially lead from bacteria being antibiotic susceptible to being
drug resistant still remain unclear. This presents an obstacle to
efforts directed at curbing the emergence of new drug-resistant
strains and at prolonging the useful life span of existing or
newly developed antibiotic drugs. We set out to examine the
initial steps leading to ciprofloxacin resistance in P. aeruginosa,
in order to ultimately develop strategies that may overcome P.
aeruginosa’s proclivity for rapidly developing new defenses.
The primary factors uncovered in ciprofloxacin resistance to
date are mutations of the DNA gyrase or topoisomerase IV (1,
16, 32, 51) and mutations in the efflux pump regulatory genes
mexR and nfxB (19). Additionally, it has been noted that gene
expression patterns are substantially altered after ciprofloxacin
exposure (8), although the specific impact upon resistance is
not yet known.
While the mutations uncovered have been associated with
high-level resistance in isolates derived after the fact, signifi-
cant questions remain unanswered. (i) Are these the only fac-
tors involved in high-level ciprofloxacin resistance? (ii) Does
resistance arise in a single step or by a multistep process?
We set out to answer these questions by first examining the
population kinetics for two strains (PAO1 and PAK) during
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exposure to ciprofloxacin to observe population responses to
the drug. Observing an apparent multistage process of resis-
tance development, we sought to uncover the specific mecha-
nisms underlying the process. One branch of that effort was
pursued using high-throughput sequencing to uncover the set
of mutations involved in this process (unpublished data). In a
second branch, we delved further into the altered patterns of
gene expression previously observed using microarray analysis,
by examining the impact upon protein expression. The results
of proteomic analysis were followed by an analysis of the ef-
fects of transposon insertion mutants on several key proteins
we identified. These efforts uncovered several intriguing ob-
servations, hinting that there may be more than meets the eye
when it comes to the initial development of ciprofloxacin re-
sistance in P. aeruginosa.
MATERIALS AND METHODS
Materials and equipment. Luria agar base Miller (LA) medium (TEKnova
Co.) and Luria broth base Miller (LB; Acros Organics) were from Fisher Sci-
entific (Pittsburgh, PA). Ciprofloxacin, 3-[(3-cholamidopropyl)-dimethylammo-
nio]-1-propanesulfonate, iodoacetamide, and dithiothreitol were from Sigma-
Aldrich (St. Louis, MO). The IPGphor for isoelectric focusing, IPG DryStrips
(18 cm; pH 3 to 11 nonlinear), 2-D Pharmalyte pH 3 to 11, IPG buffer, a
Typhoon 9400 variable mode imager, and ImageQuant software for image anal-
ysis were from GE Healthcare (Piscataway, NJ). Pefabloc SC was obtained from
Roche (Mannheim, Germany). A Protean II xi 2-D cell was obtained from
Bio-Rad (Richmond, CA). The Pro-Q Diamond phosphoprotein-specific stain
SYPRO Ruby protein gel stain and the Live/Dead BacLight bacterial viability kit
were obtained from Invitrogen-Molecular Probes (Carlsbad, CA). The Eclipse
E600 epifluorescence microscope was a product of Nikon Inc. Instrument Group
(Melville, NY). The microplate reader, a SpectraMax M2, was from Molecular
Devices (Sunnyvale, CA). Mass spectrometry for protein identification was car-
ried out with an ABI 4800 matrix-assisted laser desorption ionization–tandem
time of flight (MALDI-TOF/TOF) mass spectrometer located in the UNC/Duke
Michael Hooker Proteomics Core Facility (Applied Biosystems, Foster City,
CA).
Bacteria strains, media, culture conditions, and MIC assays. P. aeruginosa
PAO1 was obtained from the University of Washington Genome Center. The
University of Washington transposon mutant library was the source of all P.
aeruginosa mutants used in this study (18). P. aeruginosa PAK (ATCC 53308) was
provided by Matthew C. Wolfgang (University of North Carolina at Chapel Hill).
P. aeruginosa PAK is known to carry approximately 98% of the P. aeruginosa
PAO1 genes (50). All liquid cultures were grown at 35°C with aeration in a
500-ml Erlenmeyer flask with 50 ml of LB medium and supplemented with
ciprofloxacin where indicated; the culture on LA medium with ciprofloxacin was
grown for 48 h at 35°C and then CFU were counted. MICs were determined by
Etest (AB bioMerieux, AB Biodisk), using the prescribed protocol. For the
96-well microtiter plate experiments used to assay MIC heterogeneity before and
after ciprofloxacin exposure, MICs were determined using the broth dilution
method (10). For the ciprofloxacin exposure assays, 0.5 ml of overnight culture
was diluted into 50 ml of fresh Luria broth (1:100), incubated for 4 h to reach
early stationary growth phase (1  109 to 2  109 cells/ml), and then exposed to
ciprofloxacin. In all cases, viable cell counts were determined from at least two
independent experiments by serial dilution plate counting on Luria medium agar
after a 48-h incubation at 35°C.
Procedures for assaying heterogeneity of cellular responses to ciprofloxacin.
Wild-type PAK cells were exposed to 0.125 g/ml ciprofloxacin (1 the starting
MIC) in liquid LB for 6 h or 20 h. The unexposed wild-type strain and the
drug-exposed strains were then individually plated on LA medium (without
ciprofloxacin) and grown at 35°C overnight to produce colonies. We then ran-
domly picked 96 colonies from each plate (nonexposed, 6 h, and 20 h) and
inoculated them into 96-well microtiter plates for culture overnight in fresh
liquid medium (LB). The overnight bacterial culture of each well was adjusted
with sterile broth to give a turbidity equivalent of an optical density at 600 nm of
0.1. Then, a volume of bacterial suspension equal to the volume of diluted
antimicrobial solution was added to each well of ciprofloxacin to measure the
MICs (10).
Procedures for cellular protein extraction and 2D gel electrophoresis. For
two-dimensional (2D) gel electrophoresis, in two biologically independent ex-
periments the whole-cell extracts from wild-type P. aeruginosa PAK and the
ciprofloxacin-resistant strain PAK-F5 were analyzed using the O’Farrell gel tech-
nique (34). Before 2D gel electrophoresis, all protein samples were cleaned
according to the Pro-Q Diamond stain manufacturer’s protocol (39) to minimize
nonspecific staining due to phospholipids and other cell constituents. Approxi-
mately 300 g of each protein sample was applied to IPG DryStrips (pH 3 to 11
nonlinear) for the first-dimension isoelectric focusing separation. IPGphor volt-
age profiles were as follows: 30 V for 390 V  h, 1,000 V for 1,000 V  h, 2,000 V
for 4,000 V  h, 4,000 V for 6,000 V  h, 6,000 V for 12,000V  h, and 8,000 V for
14,000 V  h, with a total focusing of 38 kV  h. Prior to the 2D electrophoresis,
the IPG strips were equilibrated as described by Görg et al. (14). The second-
dimension separation was carried out by large-format 10% SDS-polyacrylamide
gel electrophoresis using a Protean II xi 2-D cell (Bio-Rad). Gels were fixed
(50% methanol–10% acetic acid overnight) prior to staining and visualization.
Additional procedures are described in the supplemental material.
Multiplexed protein and phosphoprotein fluorescence labeling and quantita-
tion. Fluorescent staining of 2D SDS-polyacrylamide gels was first performed
using Pro-Q Diamond phosphoprotein stain and subsequently SYPRO Ruby
protein stain (Invitrogen-Molecular Probes, Carlsbad, CA) following the manu-
facturer’s instructions and our previously established methods (45).
In-gel digestion, MALDI-TOF/TOF mass spectrometry, and database
searches. As described in Results, spots of interest were chosen based on changes
in the D (ProQ Diamond) and S (Sypo Ruby) values along with the D/S ratio.
The spots were excised using a 2D-iD robotic spot picker (Leap Technologies,
Carrboro, NC) into 96-well microtiter plates for automated proteolytic digestion
using an Investigator ProGest robot (Genomic Solutions, Ann Arbor, MI). The
resulting mass spectrometry (MS) data were used to identify the proteins excised
by peptide mass fingerprinting with tandem MS (MS/MS) using Mascot (36) and
our in-house-developed Genome Fingerprint Scanning (GFS) software (12),
searching against the Mass Spectrometry Protein Sequence Database (MSDB;
version 20060831) and the P. aeruginosa PAO1 genome, respectively. Typical
search parameters included two missed cleavages and 50 ppm tolerance for
peptide mass fingerprinting. Proteins were identified based on producing results
above the significance cutoff for the database search (P  0.05; Mascot MS and
MS/MS score above 74). See the supplemental material for further details on
in-gel digestion and MALDI-TOF/TOF analysis.
Ciprofloxacin resistance development assays. Three single-gene transposon
insertion mutants of P. aeruginosa PAO1, each deficient in the expression of one
gene encoding a protein determined to be differentially expressed or modified in
our analyses (strains 8773, 18230, and 631) were obtained from The University of
Washington transposon mutant library (18). We also obtained two gene insertion
mutants for use as controls (strains 30848 and 32477). Wild-type P. aeruginosa
PAO1 and each of the mutant strains were inoculated at 1:100 into fresh medium
(50 ml LB in a 500-ml Erlenmeyer flask) and incubated at 35°C for 4 h from
overnight cultures. For each mutant strain, the starting MIC was determined by
Etest, which was used to establish a concentration for ciprofloxacin exposure
equal to 4 the MIC. Ciprofloxacin was added at time zero to each culture (after
4 h of subculture incubation), and population dynamics (cell death and recovery)
were monitored for 48 h through viable cell counts at times 0, 3, 6,12, 24, and
48 h. Viable cell count data were recorded at each time point in at least two
independent experiments. Ciprofloxacin resistance levels for the wild type and
mutants were measured by Etest (MIC assay) after 24 and 48 h of ciprofloxacin
exposure.
Procedures for modeling heterogeneous responses by normal curve fitting.
Mathematica version 6.0 was used to produce normal (Gaussian) curves with the
free parameters  (mean) and  (standard deviation). Each normal curve was
then used to map a theoretical 96-well experiment to histograms using the same
set of thresholds at which the heterogeneity assay results were measured
(0.125  MIC  0.250 g/ml; 0.250  MIC  0.500 g/ml; 0.500  MIC  1.000
g/ml; 1.000 g/ml  MIC). The free parameters were manually adjusted to find
the best fit between the actual data (see Fig. 2A, below), and the synthetic plots
of the normal curve data with thresholds were applied for each of the distribu-
tions at 0 h, 6 h, and 20 h.
Simulation of ciprofloxacin resistance development kinetics in P. aeruginosa.
The Berkeley Madonna software (R. I. Macey and G. Oster, University of
California, Berkeley, CA) was used to simulate growth/death curves during
prolonged ciprofloxacin exposure. The model was provided by Bruce Levin and
colleagues from their program Model of Persistence and Mutation to Resistance
(http://www.eclf.net/programs). The model is based on a Hill function response
for the population to ciprofloxacin (40). More details, code, and model param-
eters are provided in the supplemental material.
DNA sequencing. Whole-genome DNA sequencing was performed and will be
the focus of a separate manuscript, although we discuss one result from that work
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here. Briefly, whole-genomic DNA samples from wild-type PAO1 and an iso-
lated ciprofloxacin-resistant strain, PAO1-6, were sequenced using a Roche
genome sequencer FLX system (454) in the High-Throughput Sequencing Fa-
cility at the University of North Carolina. We used the P. aeruginosa PAO1
complete genome (accession number NC_002516.2; GI 110645304) as a refer-
ence to assemble the genome and used the genome sequencer Reference Map-
per (Roche).
Additional information regarding our methods are available in the supple-
mental material.
RESULTS
Response of P. aeruginosa to 48-h ciprofloxacin exposure.
Starting with wild-type PAK and PAO1 strains, we assayed the
minimal inhibitory ciprofloxacin concentrations (MICs) by
Etest to establish a baseline. The resulting MICs were within
the expected ranges, with the PAK MIC at 0.25 g/ml cipro-
floxacin and PAO1 at 0.5 g/ml ciprofloxacin, corroborating
previous research (3).
We focused our subsequent kinetic population analyses on
P. aeruginosa cultures initially grown to stationary phase, be-
cause these cells were observed in previous experiments and
our own studies to exhibit the greatest ability to survive expo-
sure (2, 24). We examined the population dynamics in re-
sponse to ciprofloxacin exposure at concentrations ranging
from 0.5 to 8 the MIC in both strains PAO1 and PAK.
In each case, after exposure to ciprofloxacin, a significant
fraction of the initial population was killed by the drug, which
we term stage I of the antibiotic response, the “susceptible cell
death” phase. This stage is the standard and expected response
to an antibiotic exposure and lasts 6 to 12 h, as illustrated in
Fig. 1A and B. This first stage has been well studied, including
a microarray analysis of changes in gene expression (7, 9, 20),
changes in protein profiles (5), and a mathematical model of
the killing kinetics (49).
Following stage I, in every one of our experiments there was
a surviving subpopulation of cells that remained after the ma-
jority had succumbed to death by ciprofloxacin (Fig. 1A and B,
blue arrows). These cells displayed several characteristics in
common with previously characterized drug-tolerant or persis-
tent phenotypes (4, 11, 23–25).
Previous researchers have noted that “drug-tolerant” cells
display little heritability from one generation to the next, in-
dicating that the phenotype is not based on genetic changes or
mutations. We examined whether this observation applied to
our surviving cells by extracting them at various time points
after ciprofloxacin exposure, subculturing those without cipro-
floxacin, then testing their MICs. Their resulting MICs were
0.75 g/ml, slightly elevated from the baseline PAO1 wild-type
level of 0.5 g/ml but not elevated enough to be considered
resistant. We termed this population as stage II of the antibi-
otic response due to its similarities to the previously classified
drug-tolerant (persister) phenotypes.
While the cell populations exposed to the highest levels of
ciprofloxacin remained static and relatively unchanging over
48 h, we noted that at lower exposure levels a cell population
would regrow starting after about 24 h in PAO1 and 12 h in
PAK (Fig. 1A and B). We tested the heritability of drug sus-
ceptibility for these populations by extraction and subculture
without ciprofloxacin, followed by another Etest. The subcul-
tures taken from these reconstituted populations displayed
substantially increased heritable MICs. For PAK, after 40 h of
exposure at 0.5 the starting MIC (0.125 g/ml), its popula-
tion was reconstituted to 108 viable cells/ml and its heritable
resistance increased by 8-fold to an MIC of 2 g/ml (Fig. 1B,
inset). For PAO1, after 48 h of ciprofloxacin exposure at 2
the starting MIC (0.5 g/ml), its population reconstituted to
108 viable cells/ml, and its heritable resistance increased by
16-fold to an MIC of 8 g/ml. Clearly these are a different type
of cell than those we defined as stage II, based on their large
increases in MICs and their rapid regrowth in the presence of
ciprofloxacin. Hence, we labeled this as a third stage (stage III)
in the development of heritable resistance. While previous
studies have focused on the short-term antibiotic response in
stage I and stage II (2 to 6 h of exposure), our searches of the
literature revealed very little information about the mecha-
FIG. 1. P. aeruginosa growth kinetics during ciprofloxacin expo-
sure. (A) Wild-type PAO1 cells derived from an early-stationary-phase
culture were exposed to a range of ciprofloxacin concentrations from
0 to 8 the starting MIC of 0.5 g/ml. (B) Wild-type PAK cells
exposed to 0.5 the starting MIC of 0.25 g/ml ciprofloxacin, com-
pared to a nonexposed population. (Inset) Ciprofloxacin-exposed PAK
cells subsequently regrown in fresh medium with ciprofloxacin for an
additional 20 h (hollow circles), with growth curves similar to unex-
posed wild-type cells grown in fresh LB (dark circles). Blue arrows
show time points at which MICs were reassessed without significant
heritable increases, and red arrows show time points at which MICs
were reassessed and showed significant increases in MIC values (to 8.0
g/ml for PAO1 from the 2 starting MIC exposure and 2.0 g/ml for
PAK from the 0.5 starting MIC exposure). Data in are means 
standard errors from triplicate experiments.
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nisms or processes underlying the rapid and remarkable devel-
opment of resistance in these stage III cells (12-h exposure).
Solid medium experiments to determine whether resistant
cells were preexisting. The liquid culture experiments revealed
a population of cells, termed stage III, in both PAO1 and PAK
that regrew during ciprofloxacin exposure. To obtain evidence
about whether these cells preexisted in the population before
the first exposure to ciprofloxacin, we used solid medium ex-
periments with large pregrown cultures of P. aeruginosa. We
started with a 50-ml stationary-phase PAO1 culture of 109
cells/ml that was concentrated to 1 ml (5  1010 cells/ml),
then plated these directly on a series of six LA plates, each
impregnated with 1 g/ml ciprofloxacin (2 the MIC). After
24 h of incubation on the ciprofloxacin-LA plates, we scraped the
cells for resuspension in 3 ml of fresh LB and then grew them
overnight. We then assayed the MICs by Etest, and they were in
the range of 0.5 to 0.75 g/ml, showing no evidence for the
preexistence of a cell in the culture with substantially elevated
resistance.
Distribution of ciprofloxacin resistance across distinct col-
onies. To study the distribution of ciprofloxacin resistance, we
started with a 50-ml liquid culture of PAK grown to stationary
phase and then collected 1-ml aliquots both before ciprofloxa-
cin exposure and after 6 and 20 h of exposure (to 0.5 the
starting MIC, 0.125 g/ml). The washed and diluted cells were
plated separately according to exposure time point and grown
overnight on LA medium (without ciprofloxacin). We ran-
domly isolated 96 distinct colonies from each of the distinct
time point plates, transferring them individually into wells on a
96-well microtiter plate to measure their resultant pre- or post-
exposure MIC. For each time point, the measured MIC distri-
bution was heterogeneous (Fig. 2A) and could be approxi-
mately modeled with a normal distribution (Fig. 2B). As
ciprofloxacin exposure time increased, the mean of the MIC
distribution shifted higher, with the fitted normal distributions
showing mean MICs rising from 0.29 g/ml at 0 h to 0.63 g/ml
after 20 h, and their standard deviations increased from 0.08
g/ml at 0 h to 0.21 g/ml at 20 h. After 20 h of ciprofloxacin
exposure, a few selected colonies displayed at least a 4-fold
increase from the starting MIC, to 1 g/ml, and many dis-
played more than a 2-fold increase. These data indicate that
the mechanism(s) underlying stage III resistance is activated to
various degrees throughout the population after ciprofloxacin
exposure, not as a binary on/off resistance.
Mathematical modeling of tolerant and resistant popula-
tions of P. aeruginosa. We deployed a mathematical model of
drug resistance provided by Bruce Levin and colleagues (http:
//www.eclf.net/) (40) to simulate the three-stage process pro-
posed here (see the supplemental material for further details
on the model). The model represents three populations of
bacteria in an experiment: susceptible (S), tolerant/persistent
(N), and resistant (R). We used the model to examine the
question of whether resistant cells are preexisting in the pop-
ulation at the time of ciprofloxacin exposure or whether they
develop resistance after exposure. In the initial model provided
by Levin et al., the presence of 1 resistant cell/ml at time zero
(ciprofloxacin exposure) was assumed, with the resistant cell(s)
having a MIC of 20 g/ml (40 the MIC of the susceptible
PAO1 cells). Experiments were run assuming ciprofloxacin
concentrations from 0 to 4 g/ml and mutation rates as low as
1018. Regardless of mutation rate, for antibiotic concentra-
tions (A) of 4 g/ml, the population recovered to 108 cells/ml
in under 27 h (Fig. 3A), with a high slope of recovery. Com-
paring the data for an A of 2 g/ml from the model to the in
vitro experiments at the same concentration, the model’s pop-
ulation recovered much more quickly than the live cells.
In order to produce a model whose population recovered in
the slower time frame shown in vitro, we had to remove the
assumption that there were initially resistant cells in the pop-
ulation, by setting the initial resistant population R to 106
cells/ml. We then adjusted the mutation rates for various sim-
ulations, and the models whose populations recovered on a
time scale most similar to the lab experiment results had mu-
tation rates in between 109 and 108. These simulations
agreed with our solid media experiments in indicating resistant
cells are not likely present, nor are they necessary, to repro-
duce the in vitro population recovery results we observed.
Protein expression and regulation changes in stage III cip-
rofloxacin resistance. Previous studies have shown that, for
very short ciprofloxacin exposure periods (3 h), a wide array
FIG. 2. Distribution of MICs for P. aeruginosa PAK for different
ciprofloxacin exposure times. (A) Before ciprofloxacin exposure (0 h)
and after exposure for 6 or 20 h, the measured MIC distributions at
each time point are shown. (B) Normal curves fit to the heterogeneous
ciprofloxacin responses shown in panel A.  is the mean and  is the
standard deviation for the MICs of each curve. Data in panel A are
means  standard errors from triplicate experiments analyzing treat-
ment with 0.5 the starting ciprofloxacin MIC (0.125 g/ml).
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of gene expression changes occur (7, 9, 20). To examine
whether there are also substantial proteomic regulatory
changes associated with longer exposure periods (12 h), we
compared protein expression from ciprofloxacin-susceptible
wild-type PAK cells (MIC, 0.25 g/ml) to a stage III derivative
isolated after 20 h of ciprofloxacin exposure at 0.5 the start-
ing MIC. These stage III cells had a new MIC of 2 g/ml, an
8-fold increase over the wild type, and we hereafter refer to
them as PAK-F5 cells. We analyzed extracted protein samples
from two independent biological replicates by multiplexed 2D
gel electrophoresis (43). We stained the proteins in the gels for
phosphoprotein abundance (Pro-Q Diamond) and for total
protein abundance (SYPRO Ruby).
Of the approximately 650 protein spots observed on the gels,
three proteins displayed visually identifiable and repeatable
differences in expression between PAK-F5 and unexposed
wild-type cells. Two of those were differentially phosphory-
lated, having a 4-fold increase in the ratio of phosphorylated to
total protein (Fig. 4) for PAK-F5 cells versus wild type. These
proteins were identified by mass spectrometry as PA0265 (suc-
cinate-semialdehyde dehydrogenase [SSADH], encoded by
gabD) and PA3570 (methylmalonate-semialdehyde dehydroge-
nase [MMSADH], encoded by mmsA). Surprisingly, neither of
these had been previously identified as phosphoproteins in P.
aeruginosa. They are putatively involved in amino acid metab-
olism and/or energy production (46). A third protein displayed
6-fold-higher total protein abundance in PAK-F5. It was iden-
tified by mass spectrometry as PA3539, a conserved hypothet-
ical protein of unknown function, encoded by the gene yaaA
(see Table S1 in the supplemental material).
Examining the role of the identified proteins in the survival
of P. aeruginosa during ciprofloxacin exposure. We then asked
the question: if we knocked out the genes encoding each of these
proteins, would this affect survival, recovery, and/or resistance
development of P. aeruginosa after ciprofloxacin exposure?
We obtained PAO1 mutants with transposon disruption of
each of the encoding genes, along with two other mutant
strains as controls, one without a functional phoU gene and the
other without a functional Glu-tRNA (Gln) amidotransferase
subunit A protein (encoded by gatA) (see Table S2 in the
supplemental material). The phoU control mutant was chosen
because a homologous protein was previously implicated in the
formation of the persister phenotype (stage II) in Escherichia
coli (27). The gatA control was chosen because its protein was
visible on the same proteomic gels as the identified proteins yet
appeared unchanged in expression between wild-type and re-
sistant strains.
We determined the starting MICs for each mutant and
then assessed their population kinetics after ciprofloxacin
exposure at 2, 4, and 8 their starting MICs. The mu-
tant strains displayed stage II surviving population ratios
similar to the wild type and mutant controls (Fig. 5A, bot-
tom panel; see also Fig. S1 in the supplemental material).
However, the ability to reconstitute a stage III population in
the continuing presence of ciprofloxacin was substantially
muted by gene disruption (Fig. 5A, top panel; see also Fig.
S1). The differences between strains were most apparent at
4 the starting MICs. The control mutants did not have
similarly negative effects on stage III population recovery.
We then studied whether the ability to develop heritable
resistance in the mutants (stage III) was inhibited. Each of the
wild-type PAO1, control, and candidate strains was exposed to
4 and 8 the starting MICs of ciprofloxacin in liquid culture
for 24 and 48 h. In wild-type PAO1, resistance increased 50-
fold to a clinically significant level following 48 h of exposure at
4 the starting MIC (Fig. 5B). In the gatA control mutant, the
result was very similar. The phoU control mutant showed re-
duced resistance compared to the wild-type after ciprofloxacin
exposure at 8 the MIC, but with exposure to 4 the MIC
resistance developed to about 35 its starting MIC.
In contrast to both controls, each of the stage III-associated
mutant strains showed dramatic decreases in the development
of heritable resistance after exposure at either 4 or 8 the
starting MIC. None of them achieved a clinically significant
drug resistance level. The resistance inhibition was strongest
with the mmsA mutant.
We measured whether the reduced abilities of the candi-
dates to survive exposure was due to a pleiotropic growth
defect. The candidate mutants did not present any significant
growth defects prior to ciprofloxacin exposure (see Fig. S2 in
the supplemental material). Growth defects were only appar-
ent after ciprofloxacin exposure, upon stage III recovery.
FIG. 3. Mathematical model of resistance development in P.
aeruginosa based on computer modeling code developed for use in the
Berkeley Madonna modeling environment, from Levin and colleagues
(see the supplemental material for further information). We adapted
the code to model the three-stage process postulated here. Three
populations were assumed in this model: susceptible (S) cells, pheno-
typically tolerant (N) cells, and genetically resistant (R) cells, with
densities expressed as bacteria per ml. (A) The initial model, starting
with one resistant cell per ml (R 	 1), one tolerant cell per ml, and the
remainder as susceptible. Simulations were run for antibiotic concen-
trations (A) of 0 g/ml up to 4 g/ml. The mutation rate (mur) was 2 
109. (B) Simulations where the initial resistant cells were set to be
effectively zero (R 	 106 cells/ml). Otherwise, we used the same
parameters as in the previous simulations. Dashed lines show the
resistant mutant population, and solid lines show the total population
of live cells versus time.
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Effects of culture size on stage III development. In wild-type
P. aeruginosa, we observed that the development of stage III
resistance and the resulting population recovery was af-
fected by culture volume (i.e., population size) and cipro-
floxacin concentration (see Fig. S3A and B in the supple-
mental material). Examining this in detail, we measured
PAO1 ciprofloxacin kill/regrowth curves in liquid culture
volumes of 5, 25, and 50 ml, at both 2 and 4 the start-
ing MIC.
At 2 the starting MIC, there was a clear recovery of the
FIG. 4. Multiplexed 2D gel electrophoresis comparison of protein expression for wild-type PAK cells at early stationary phase versus the derivative
PAK-F5 strain with ciprofloxacin resistance (at 8 the starting MIC, 2.0 g/ml). (A) Proteins were visualized using the Pro-Q Diamond phosphoprotein
stain (light blue) and SYPRO Ruby total protein stain (red). To the right, the ratios of the Pro-Q Diamond dye signal to the SYPRO Ruby dye signal
(abbreviated as the D/S ratio) for two spots of interest are shown, as an approximate measure of the phosphorylation level relative to the total protein
of that species. (B) Comparison of total protein concentration using SYPRO Ruby stain. The image volume on the right panel is the mean  standard
error of the ratio between the two gels for our identified protein, YaaA, representing a 6-fold expression level change compared to four nearby spots
(labeled by the red cross) that were chosen as internal controls. The experiments in panels A and B were run in biological duplicates.
FIG. 5. Ciprofloxacin response profiles for candidate mutants versus controls. (A) PAO1 strain cultures starting with 109 viable cells were then
exposed to ciprofloxacin at 4 the starting MIC, as measured by Etest for each strain. (Bottom) Relative population reduction (stage II population versus
stage I population) after 24-h ciprofloxacin exposure. Candidates and controls show similar population reductions at 24 h. (Top) Relative population
recovery (stage III population versus stage II population) after 24 additional hours for the same cultures, based on the ratio of viable cell counts at 48 h
versus 24 h. Data are means  standard errors from triplicate experiments. (B) After 24-hour and 48-hour ciprofloxacin exposure in liquid medium, at
4 and 8 the starting MIC, control and candidate strains were retested to determine MIC levels relative to the starting level. The candidate strains
responded with weak MIC increases relative to the control strains, and the phoU mutant also responded weakly after exposure to 8 its starting MIC.
VOL. 54, 2010 CIPROFLOXACIN RESISTANCE IN PSEUDOMONAS AERUGINOSA 4631
population with stage III resistance, regardless of culture vol-
ume (see Fig. S3A in the supplemental material). However, at
4 the starting MIC, only the 50-ml culture was reconstituted
(see Fig. S3B). This result can be explained by our model of a
normal distribution for MICs in the population (Fig. 2).
Depending on both the exposure level and population size,
there may or may not be enough cells that develop stage II
resistance above the survival threshold to reconstitute the pop-
ulation (Fig. 6). From the experiment shown in Fig. S3A and B
in the supplemental material, we estimate the threshold to be
about 105 total cells that must survive in stage II in order to
lead to a stage III population that reconstitutes.
Effects of other antibiotics. To investigate the response of
both the wild-type PAO1 and the transposon mutants to other
antibiotics, we assessed their MICs by Etest for a panel of
antibiotics representing the fluoroquinolones, 
-lactams, and
aminoglycosides (see Table S3 in the supplemental material).
For the quinolones, the mutant candidate strains exhibited
4-fold-reduced ciprofloxacin MICs and 8-fold-reduced levo-
floxacin MICs. For the 
-lactam imipenem there was a 2- to
4-fold reduction in the MIC. There appeared to be little effect
of the gene disruption mutants on the MICs for other classes
of antibiotics.
DISCUSSION
Our results show strong evidence for a multistage drug ad-
aptation process in P. aeruginosa. In stage I, the susceptible
population (S) is killed off. This leaves stage II cells, surviving
at a ratio of 1 in 104 to 1 in 105, and these cells appear to exhibit
drug-tolerant phenotypes (N) that are non- or slow growing
and do not display significantly increased MIC levels. Finally,
after continuous exposure at moderate ciprofloxacin levels
(8 the MIC), a stage III population arises that is rapidly
growing and exhibits substantially increased MIC levels. While
a process of mutation appears to underlie the stage III cells
(unpublished data that will be reported separately), it appears
that nongenetic regulatory mechanisms may also play an im-
portant role in the resistance phenotype. In the PAK-F5 strain
we identified three significantly altered proteins, two of which
appear to have an effect via phosphorylation and appear to be
essential for the progression to stage III.
We naturally wondered how these results could be related to
previous studies that have shown a gyrA mutation as one pri-
mary molecular mechanism for ciprofloxacin resistance in P.
aeruginosa (16, 32). Our whole-genome sequencing of PAO1
stage III cells confirmed that a gyrA mutation was present in
the stage III cells. However, we found a variety of other mu-
tations, none of which has been previously associated with
ciprofloxacin resistance. We are presently assaying these mu-
tations for their functions in ciprofloxacin resistance. Yon-
ezawa et al. suggested that the gyrA mutation, while necessary
for ciprofloxacin resistance, may not be sufficient for resis-
tance. There is evidence that changes to other genes, such as
parC, and the efflux pump regulator are necessary to produce
high-level ciprofloxacin resistance in P. aeruginosa (16, 32, 51).
The multistage process of ciprofloxacin resistance in P.
aeruginosa that we illustrated here raises a significant question:
does the stage III resistance exist in the population before the
bacteria are exposed to ciprofloxacin? One reason for thinking
this is that the population sizes are vastly larger before expo-
sure to ciprofloxacin than after. It might be argued that it
would be improbable for mutations to arise out of the rela-
tively small stage II population to produce stage III.
Yet the evidence all points to a different scenario: that the
mutation(s) and regulatory changes evident in stage III arise
directly from the stage II population, not from a preexisting
mutant in the population. The evidence also indicates that the
process is stepwise and heterogeneous, not a single, large jump
to a higher resistance level. While this result is surprising when
considered in the context of current theories, there is support
for higher mutation rates in ciprofloxacin-exposed cells via the
SOS response (29). When mutation rates are increased artifi-
cially via a mutS deletion, PAO1 can develop high-level cipro-
floxacin resistance on the order of 1 in 106 cells per generation
(35).
This is compatible with our results that demonstrated a
required volume of cells of over 20 ml to develop stage III
resistance. The stage II population cells are present at 104 to
105 cells per ml, and therefore, when the volume is 20 ml, we
had a total cell number of 106 in the culture. If we speculate
that mutation of a tolerant cell to a resistant cell is occurring at
a rate (mur) of 107 per hour (with 2 generations per hour),
we would expect the following: total cells  mur  106 cells 
107 mutations/h  101.5 h, which results in three resistant
mutants obtained in the culture.
Since only one resistance mutant is initially required to pro-
duce a growing population of stage II resistant cells, this ex-
periment would quickly produce a recovered population of
resistant cells as soon as one of these resistant cells occurred.
However, if we consider the case of a 1-ml volume, in which
FIG. 6. Thought experiment for the effects of population size and
ciprofloxacin concentration on the development of stage III resistance.
The model shows sample normal curves based on the parameters
derived for the 20-h exposure curve shown in Fig. 2B (, 0.63 g/ml;
, 0.21 g/ml). The blue curve is scaled at 1/10 of the area of the red
curve, illustrating the relative population sizes between a 5-ml culture
and 50-ml culture. When cells were exposed to 2 the starting MIC
(0.5 g/ml), the majority of both populations developed resistance
above this threshold, producing sufficient numbers of survivors to sub-
sequently reconstitute the population (black hashed line on the left).
However, when exposed to 4 the starting MIC, sufficient culture
volume was required to allow reconstitution, as modeled by the black
dotted line on the right. In this model, only the rare outlier members
on the far right of the distribution will survive (red and blue shaded
areas). When the volume is insufficient, there will not be enough cells
above this threshold to survive and reconstitute the population (blue
shaded area).
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we did not observe resistance developing, then we get have the
following: total cells  mur  106 cells  107 mutations/h 
101.5 h, resulting in 0.3 resistant mutants. In other words, the
volume and/or time span studied was not sufficient to produce
the single mutant needed for growth and recovery of a stage III
population.
The question remains whether this is an all-at-once mutation
or whether multiple mutations must occur for resistance. Our
evidence to date points to the production of stage III mutants
being a multistep process, in which case the actual intracellular
mutation rate may be higher, resulting in time for enough
mutations to accumulate to produce a resistant mutant.
The notion that our nongrowing stage II cells produce mu-
tants is supported by evidence that nondividing E. coli cells
exposed to ciprofloxacin over 7 days produced adaptive muta-
tions (42).
This leaves an open question: what role do the protein reg-
ulatory changes we observed play in stage III resistance? Our
gene disruption results show that they play a vital role in
resistance development for stage III, yet they are not necessary
to produce stage II.
One possible explanation for their role would be in support
of drug efflux pump activation, which is important for P. aerugi-
nosa in ciprofloxacin resistance (30, 37, 44). The proteins
MMSADH and SSADH may catalyze energy production, pro-
ducing ATP that supports “energy-hungry” processes, like the
efflux pumps (Fig. 7). These pumps, such as MexAB-OprM,
operate using energy from hydrolysis of ATP or from the
proton motive force derived from charge gradient across the
cell membrane (33). If the pumps become activated in drug-
resistant phenotypes, the energy production pathways feeding
them would also require activation. There is evidence from the
literature that an increased ATP/ADP ratio leads to increased
ciprofloxacin susceptibility in wild-type E. coli cells (26), which
contraindicates our hypothesis that these proteins produce
more energy to support energy-hungry processes like efflux
pumps and/or the SOS response. However, we’re not sure that
relating the effects of ATP/ADP ratios in wild-type E. coli to
ciprofloxacin-resistant P. aeruginosa is a valid comparison.
An alternative hypothesis for the role of these proteins
stems from the observation that two of them produce NADH
as a reaction product (Fig. 7). NADH is produced in response
to environmental stress (38) as a reducing agent that prevents
oxidative damage. There is some evidence that major classes of
bactericidal antibiotics, including the 
-lactams, aminoglyco-
sides, and quinolones, stimulate the production of hydroxyl
radicals that may contribute to oxidation-mediated cell death
(21). Therefore, we might postulate that NADH is upregulated
by the phosphorylation of our identified proteins to buffer
oxidative stress induced by ciprofloxacin.
FIG. 7. Hypothetical model for the role of the phosphorylated proteins MMSADH and SSADH, characterized as playing a role in stage III
resistance. Efflux pump systems are a known mechanism for innate drug resistance in P. aeruginosa, and this model shows the resistance-
nodulation-division (RND) tripartite efflux system. RND transporters require energy for activation and operation. The identified proteins are both
NAD-dependent aldehyde dehydrogenases that may be involved in electron transfer, supporting an energy conversion pathway to produce ATP.
NADH is a by-product of the reactions catalyzed by both proteins, which may ameliorate oxidative stress induced by antibiotics like ciprofloxacin.
The substrate for MMSADH is methylmalonate-semialdehyde plus coenzyme A (CoA), and the product is propionyl-CoA plus NADH. The
substrate for SSADH is succinate semialdehyde, and the product is succinate plus NADH.
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Interestingly, these hypotheses are not mutually exclusive:
both are compatible with all the data we have available. Could
it be that evolution has wrapped two important responses to
antibiotic resistance into one pathway? While the evidence is
not yet strong, it is an intriguing possibility.
Regardless of the mechanism(s), the results make it clear
that the development of resistance in P. aeruginosa is a multi-
faceted process involving three distinct stages: stage I, suscep-
tible cell death; stage II, tolerant cell survival without growth
or resistance; stage III, resistant cell development and popu-
lation regrowth. In addition, the three proteins we found as-
sociated with heritable drug resistance demonstrate that there
are preexisting cellular pathways in P. aeruginosa that act in
support of genetic mutations, together producing heritable re-
sistance to ciprofloxacin. This knowledge may ultimately lead
to new strategies that prevent development of drug resistance
to ciprofloxacin and other antibiotics.
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